HCP Targeting & Segmentation — Pharma Marketing Playbook (2026)

HCP targeting is the practice of identifying, prioritizing, and reaching licensed healthcare providers — physicians, nurse practitioners, physician assistants, pharmacists — whose prescribing behavior a pharma brand wants to influence. It looks nothing like consumer targeting. Instead of cookies and lookalike audiences, the spine of HCP targeting is the National Provider Identifier (NPI), a 10-digit number issued by CMS that stays with a clinician for life. Around that identifier, brand teams stitch together specialty codes, prescribing deciles, behavioral personas, first-party rep-call history, third-party Rx panels from providers like IQVIA and Symphony Health, and digital engagement from endemic publishers like Doximity and Medscape. Done well, the result is a segmented universe of 15,000 to 60,000 providers and a clear plan for which channel, message, and frequency each segment should receive. Done poorly, it is overlapping lists that waste field time and digital spend.

What Is HCP Targeting?

HCP targeting answers four practical questions: who is a candidate prescriber for this brand, how important is each candidate, what do they already know about the product, and which channels reach them. Each question maps to a different attribute on the HCP record.

Identity (NPI). The NPI anchors everything. It is public, free from CMS NPPES, and uniquely identifies a provider across health systems and employers. See the CMS NPPES NPI Registry for the authoritative file.

Specialty and sub-specialty. Taxonomy codes on the NPI record distinguish a general cardiologist from an electrophysiologist, or an endocrinologist from a diabetologist. For specialty brands, sub-specialty often matters more than specialty.

Prescribing decile. Decile is a rank from 1 (lowest) to 10 (highest) based on TRx (total prescriptions) in a therapeutic category over a rolling window — usually 52 weeks. A decile-10 oncologist writes orders of magnitude more scripts than a decile-3. Brand teams usually concentrate commercial effort on deciles 6 through 10.

Behavioral attributes. NBRx (new-to-brand prescriptions) and NRx (new prescriptions, including switches from a competitor) tell a different story than TRx. A decile-8 prescriber who never writes NBRx for your brand is a different target than a decile-5 who just wrote their first three NBRx last month. Behavioral segmentation layers these signals on top of the decile.

Unlike consumer audiences, HCP segments are small and durable. A brand might have 22,000 target HCPs for a year and only replace a few hundred each quarter as new providers enter practice or existing ones change behavior.

HCP Segmentation Frameworks

HCP segmentation is the process of grouping those identified providers into strategic cohorts. Five frameworks dominate commercial planning:

1. Prescriber decile segmentation. The oldest and still most common — rank providers 1 to 10 by category TRx, focus the field force on high deciles, use digital to cover lower deciles. Simple to operationalize, blunt as a strategy.
2. Adopter lifecycle. Innovators, early adopters, early majority, late majority, laggards. Useful at launch when the brand's goal is to seed evangelists who will influence peers.
3. Behavioral persona. Combines Rx behavior with engagement signals — "high-decile loyalist," "high-decile competitive user," "growing NBRx writer," "dormant former prescriber." These cohorts drive messaging, not just media weight.
4. Patient-volume segmentation. For therapies that treat a specific condition, patient counts per HCP (via claims data) can be more predictive than category TRx. A rheumatologist with 400 biologic-eligible patients is a bigger opportunity than one with 40, regardless of historical writing.
5. Specialty and sub-specialty segmentation. For orphan, rare disease, or sub-specialty drugs, the universe may only be 2,000 to 8,000 providers nationally. Here the framework collapses into precision targeting of named centers of excellence.

Most brands run two or three frameworks in parallel: decile for sizing, behavioral for messaging, sub-specialty for precision.

Data Sources for HCP Targeting

HCP targeting data falls into three tiers, and a well-run brand team feeds all three into a single NPI-keyed customer data platform.

First-party data. Rep call notes, CRM (typically Veeva CRM or Salesforce Health Cloud), sample distribution, speaker program attendance, medical information requests, and website/portal logins. First-party data is the most valuable because it reflects how the HCP has already engaged with your brand.

Third-party Rx and claims data. A handful of providers sell de-identified prescription and medical claims data licensed to pharma brands. Listed alphabetically:

• Clarivate (which acquired DRG) provides therapy-area market research, epidemiology, and prescribing landscape studies.
• Definitive Healthcare offers an NPI-keyed provider database with affiliations, procedure volumes, and claims-derived metrics, widely used for account mapping.
• IQVIA is the largest Rx data vendor, supplying Xponent (retail Rx), DDD (Drug Distribution Data for non-retail), and segmented prescriber files that are foundational for most brand teams.
• Symphony Health (part of ICON) offers PatientSource and Integrated Dataverse (IDV) — alternatives for Rx and claims analytics, often used for second-source validation.
• Veeva Link and Veeva OpenData provide a maintained master of HCPs and health-care organizations with affiliation graphs.

Each vendor plays a defined role in the ecosystem. Many brand teams license two Rx data sources for cross-validation and use Veeva or Definitive for the provider master.

Digital and endemic publisher data. Physicians spend working time on professional platforms, and those platforms sell NPI-matched ad inventory and engagement data. Major endemic publishers include:

• DeepIntent — programmatic DSP specialized in NPI-level targeting across CTV, display, and video.
• Doximity — the largest U.S. physician network; its ad product targets by specialty, NPI list, or behavior.
• Epocrates — point-of-care drug reference used widely by prescribers.
• HCN (Healthcare Communications Network) — email and display across a network of specialty sites.
• Medscape (WebMD) — clinical news and CME; offers NPI-matched display and sponsored content.
• PulsePoint — programmatic inventory with healthcare data overlays.

Feeding first-party, third-party, and digital signals into one NPI-keyed warehouse is what turns "data sources" into "targeting."

Identity Resolution — NPI as the Spine

Every dataset worth joining for HCP targeting either carries an NPI natively or can be matched to one via a deterministic match (name + state + license) against the NPPES registry. The NPI is what lets a brand team connect a rep call in Veeva to a programmatic impression on Doximity to an Rx event in an IQVIA panel — all for the same physician.

Practical identity resolution steps:

• Canonical master. Adopt one provider master — typically Veeva OpenData, Definitive Healthcare, or an internal build from NPPES — and make every system join to it.
• Deterministic match. Prefer exact NPI matches. Where a source has only name and state (older speaker program rosters, some digital exchanges), run a match-back against NPPES with blocking on last name + state + license number where available.
• Affiliation graph. Many HCPs practice at multiple sites. Maintain HCO (healthcare organization) affiliations separately from the HCP record; otherwise targeting a hospital system will double-count providers.
• HIPAA guardrails. NPI-keyed data that has been de-identified per the Safe Harbor method (see HHS guidance) is typically not PHI. It becomes regulated PHI again when joined with data from a Covered Entity — for example, if you bring in electronic medical record data tied to a provider's patient panel. Brand teams should keep de-identified HCP targeting data on one side of a well-documented firewall and any Covered-Entity data on the other.

Targeting by Lifecycle Stage

The same HCP universe needs different targeting priorities at launch, growth, and loss of exclusivity (LOE).

Launch. Targeting skews toward innovators and early adopters — KOLs, sub-specialists, and high-decile writers in the relevant category. Media supports the field force with heavy reach against a small list (often fewer than 10,000 HCPs). NBRx is the key metric because there is no installed base yet.

Growth. The universe widens. Brand teams expand from the top two deciles to deciles 6 through 10 and begin behavioral targeting — competitive users, loyalty maintenance, dormant-prescriber reactivation. The mix shifts from pure reach to frequency management and messaging variants.

LOE. Once generic or biosimilar competition enters, targeting narrows again to high-value loyalists and patients already stable on therapy. The commercial question becomes retention rather than acquisition, and field coverage usually shrinks while digital holds or grows as the more cost-efficient channel.

Measurement — Connecting Targeting to Rx Lift

Targeting is only as good as the measurement that closes the loop. Three methods dominate:

• Match-back analysis. Link exposed HCPs (those who saw ads, received calls, or attended programs) back to their Rx behavior via IQVIA or Symphony Health panels. Compare exposed vs unexposed cohorts over a pre-defined post-period (often 8 to 13 weeks) to measure Rx lift.
• Test-and-control design. Hold out a matched control group up front — matched on decile, specialty, geography, and baseline Rx. The difference between test and control on TRx, NBRx, or NRx per HCP over the measurement window is the causal lift estimate. This is methodologically stronger than match-back alone.
• Marketing mix modeling (MMM). At the brand level, MMM decomposes total Rx into contributions from personal promotion, non-personal promotion (digital, email, print), DTC, samples, and baseline demand. MMM does not give per-HCP lift but it sizes channel contribution and guides budget allocation across targeting channels.

All three methods benefit from the same underlying plumbing: an NPI-keyed event stream (exposures, calls, Rx) stored in a warehouse with enough history to support pre/post comparisons.

10-Point HCP Targeting & Segmentation Checklist

1. Adopt one provider master (Veeva OpenData, Definitive, or NPPES-derived) and join everything to it.
2. Refresh NPI-level Rx data at least monthly; weekly for launch brands.
3. Maintain both HCP and HCO (organization) records with an affiliation graph.
4. Use at least two segmentation frameworks in parallel — decile for sizing, behavioral for messaging.
5. Carry specialty and sub-specialty taxonomy, not just specialty.
6. Track TRx, NBRx, and NRx separately — they drive different decisions.
7. Document the Safe Harbor de-identification boundary between HCP targeting data and any Covered-Entity data.
8. Reconcile first-party CRM touches with third-party Rx panels on the same NPI.
9. Reserve a randomized control group at campaign design time for lift measurement.
10. Review segment definitions at least semi-annually — behavioral cohorts drift as the market changes.

How Improvado Unifies HCP Targeting Data

Improvado is a marketing data platform that consolidates first-party and third-party HCP data sources into a single NPI-keyed warehouse. It includes pre-built connectors for Doximity, Medscape, PulsePoint, DeepIntent, Epocrates, Aptitude Health, HCN, Outcome Health, and more — 59+ endemic HCP publishers total — alongside 1000+ connectors to general ad platforms, CRMs, and analytical tools. Rx and claims feeds from IQVIA, Symphony Health, and Veeva are ingested via SFTP or API and landed into the same schema, so campaign exposures and Rx events sit in one place keyed on NPI. New connectors are added in days, not weeks.

Improvado's architecture runs above the tracking layer — it handles aggregated campaign and spend data and de-identified NPI-keyed Rx, not individual patient tracking. For Covered-Entity clients a BAA is available; the platform is HIPAA-compatible by architecture. The Extract, Transform (via Marketing Data Governance), and Load stages deliver data to Snowflake, BigQuery, Redshift, Looker, Tableau, or Power BI. On top of the warehouse, agentic data pipelines and an AI Agent let brand teams ask natural-language questions — for example, "Show me high-decile Brand X adopters in cardiology who engaged with three or more Doximity placements last quarter" — and get an answer against the unified data model without writing SQL.

FAQ

What is the difference between HCP targeting and HCP segmentation? Targeting is the act of selecting which providers to reach. Segmentation is the act of grouping providers into strategic cohorts (by decile, behavior, specialty, etc.) that inform how to reach them. Segmentation feeds targeting.

Is NPI-keyed prescribing data considered PHI under HIPAA? NPI-keyed Rx data that has been de-identified under the HIPAA Safe Harbor method is typically not PHI — it describes a provider, not a patient. It becomes regulated PHI when joined with data from a Covered Entity, such as electronic medical record data tied to identifiable patients.

What is an HCP decile? A decile is a rank from 1 to 10 based on a provider's category TRx over a rolling period, typically 52 weeks. Decile 10 represents the top 10 percent of writers in that category.

How many HCPs does a typical pharma brand target? Most brands work with a target universe of 15,000 to 60,000 providers, segmented into 8 to 15 behavioral cohorts. Rare-disease and sub-specialty brands may work with 2,000 to 8,000.

What are the main third-party HCP data providers? Listed alphabetically, the major providers include Clarivate (which acquired DRG), Definitive Healthcare, IQVIA, Symphony Health (ICON), and Veeva (via Link and OpenData). Each plays a different role — Rx panels, provider master, affiliations, or market research.

How do brand teams measure whether targeting worked? Three methods: match-back analysis (exposed vs unexposed Rx comparison via IQVIA or Symphony Health panels), test-and-control designs with a matched holdout, and marketing mix modeling for channel-level contribution. Test-and-control is the methodologically strongest of the three.